Key Takeaways
- Investment in crop genomics is rotating away from corn and soybeans toward wheat and rice — crops central to global food security.
- The strategic objective has shifted from ‘convenience traits' like herbicide tolerance to ‘survival traits' such as drought and flood resilience.
- Regulatory approvals, including Syngenta's X-Terra® hybrid wheat in France, signal commercial viability for genomically-enhanced staple crops.
- India's release of 31 new rice varieties in 2025 reflects a dual-track strategy combining biofortification with climate resilience.
- Tool-sharing arrangements, such as Pairwise licensing its Fulcrum® platform to IRRI, are expanding crop genomics reach into smallholder markets.
A Reallocation of Genomic Capital
For the better part of two decades, the commercial logic of crop genomics pointed in one direction: corn and soybeans. The two crops offered industrial scale, an established trait market built around herbicide tolerance and insect resistance, and a concentrated buyer base in large-scale commodity agriculture. Genomic R&D investment followed this logic reliably.
The data from the first quarter of 2026 indicates that this concentration is breaking down. Capital and scientific attention in crop genomics are rotating toward wheat and rice — the crops that feed the majority of the world's population — and the strategic objectives driving that rotation are different in character from what drove the corn and soy era.
Crop Genomics and the ‘Survival Trait' Agenda
From Farming Ease to Climate Resilience
The distinction being drawn in the sector is between ‘convenience traits' and ‘survival traits.' The herbicide tolerance and insect resistance traits that defined the first generation of crop genomics investment were primarily designed to make farming easier and more economically efficient. The traits being prioritised in wheat and rice development in 2025 and 2026 are designed to keep crops viable in conditions that are becoming less predictable.
Drought tolerance, flood resistance, heat stability, and salinity tolerance — collectively described as abiotic stress resilience — are now listed as primary objectives in a growing proportion of new product development activity tracked by the sector. This is not a marginal shift. It reflects a fundamental change in what buyers of genomic innovation are asking for.
Wheat's Genomic Leap
Wheat presents particular technical challenges for crop genomics. Its genome is large and complex, and traditional breeding timelines are long. The commercial economics of wheat have historically made it a lower-priority target for expensive gene-editing research relative to the higher-margin corn and soy markets.
That calculus is changing. Wild Bioscience is applying AI-driven discovery tools to develop precision-bred wheat varieties, while Syngenta has reached a significant commercial milestone with French regulatory approval of its X-Terra® hybrid wheat — the product of a 15-year development process targeting yield stability in volatile climatic conditions.
“Companies are moving beyond traditional breeding. Wild Bioscience is leveraging AI-driven discovery to develop precision-bred wheat, while Syngenta has reached a 15-year milestone with the French approval of X-Terra® hybrid wheat, aiming for yield stability in a volatile climate.”
Bioceres Crop Solutions is separately advancing its HB4® drought-tolerant wheat in the U.S. market, targeting the expansion of viable growing geographies as traditional wheat-belt regions face increased thermal and water stress.
Rice as a Climate and Nutrition Instrument
In rice, the strategic pivot is even more explicit. India's release of 31 new rice varieties in 2025 encapsulates the dual-track logic now operating in this segment of crop genomics: biofortification on one track — specifically zinc enrichment — and climate resilience on the other, including flood and drought tolerance traits.
The environmental dimension of rice genomics has also become more prominent. String Bio's CleanRise® technology is targeting traits that reduce nitrogen use in rice cultivation by approximately 25% and lower greenhouse gas emissions from rice paddies by 30 to 40%. The commercial viability of these emissions-related traits positions rice crop genomics as a potential participant in carbon markets — a dimension of value that did not exist in the earlier phase of the industry.
The Democratisation of Crop Genomic Tools
Licensing Into Underserved Markets
One of the structural features of the current phase of crop genomics activity is the use of platform licensing to extend research capacity into markets that private-sector investment has historically not reached. Pairwise has made its Fulcrum® CRISPR platform available to the International Rice Research Institute (IRRI) specifically to enable the development of climate-resilient rice varieties for smallholder farmers — a segment that generates limited commercial return but represents a significant share of global food production.
This model of ‘tool sharing' reflects a maturation in the crop genomics sector. Proprietary CRISPR tools, once closely guarded, are being treated as enabling infrastructure whose broader deployment serves both commercial and reputational purposes for the firms offering them.
Non-GMO Certification as a Market Access Strategy
The regulatory dimension of the wheat and rice pivot is also relevant to how products reach market. Much of the crop genomics activity in 2025 and 2026 is being conducted under New Breeding Technique frameworks that allow precision-bred varieties to be classified outside the traditional GMO regulatory pathway. Salicrop's non-GMO seed priming for saline irrigation, for example, targets markets and buyer segments where a GMO classification would restrict commercial uptake.
The practical effect is to compress the path from validated edit to commercial field application, which aligns with the broader industry shift toward speed-to-market as the primary performance metric.
Beyond Staple Crops: Nutrition and Flavour as Crop Genomics Objectives
The rotation toward global staples is the dominant signal, but it coexists with a parallel development in the sector: the application of genomic tools to niche, consumer-facing crops on the basis of culinary quality and nutritional density rather than yield or resilience.
NuCicer's development of higher-protein chickpeas and Row 7 Seed Company's work on the ‘Starling' sweet potato — targeted at organic and premium retail markets — represent a different expression of what crop genomics can deliver. These are products being differentiated on grocery shelves, not in commodity silos. The implication is that the addressable market for crop genomics innovation is wider than the staple crop security framing suggests.
Read the entire report here.
